Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 9/20 | 0.43 |
| ▸ | ACVRL1 | P37023 | 9/20 | 0.43 |
| ▸ | RET | P07949 | 4/20 | 0.43 |
| ▸ | ROS1 | P08922 | 4/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.37 |
| ▸ | RHEB | Q15382 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 9/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452940 | 1.00 | NTRK1 (0.43) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL768308 | 0.83 | NTRK1 (0.49) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL794064 | 0.83 | NTRK1 (0.49) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL450332 | 0.82 | PRKAG1 (0.36) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL441580 | 0.82 | PRKAG1 (0.36) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL794119 | 0.81 | IGF1R (0.64) | NTRK1RETROS1METNTRK3 | |
| SCHEMBL767739 | 0.81 | IGF1R (0.64) | NTRK1RETROS1METNTRK3 | |
| SCHEMBL767740 | 0.81 | IGF1R (0.64) | NTRK1RETROS1METNTRK3 | |
| SCHEMBL438772 | 0.81 | NTRK1 (0.45) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL773575 | 0.81 | NTRK1 (0.44) | NTRK1ACVRL1RETROS1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| WO-2012037155-A2 | TYROSINE KINASE INHIBITORS | GTX, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | NTRK1 65/4885ACVRL1 592/4885RET 11/4885 |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | NTRK1 65/4885ACVRL1 592/4885RET 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.